Clinical Trial Update: A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma [Phase 2]

View source ↗

Summary

Phase 2 study of durvalumab in combination with tremelimumab for malignant pleural mesothelioma was terminated, with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Mesothelioma | Phase 2 | Status: TERMINATED | Results posted: 2019-11-12